These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33349788)

  • 1. A Dermatologist's Guide to Implementation of Gene Expression Profiling in the Management of Melanoma.
    Kwatra SG; Hines H; Semenov YR; Trotter SC; Holland E; Leachman S
    J Clin Aesthet Dermatol; 2020 Nov; 13(11 Suppl 1):s3-s14. PubMed ID: 33349788
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
    Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
    JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group.
    Farberg AS; Marson JW; Glazer A; Litchman GH; Svoboda R; Winkelmann RR; Brownstone N; Rigel DS;
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):807-823. PubMed ID: 35353350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating 40-GEP Testing to Improve Clinical Recommendations for Adjuvant Radiation for Cutaneous Squamous Cell Carcinoma: Multidisciplinary Consensus Guidelines.
    Gopal R; Marquardt M; Singh G; Tolkachjov SN; Arron ST
    J Clin Aesthet Dermatol; 2024 Mar; 17(3 Suppl 2):S3-S8. PubMed ID: 38495846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
    Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
    Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Gene Expression Profiling to Personalize Skin Cancer Management.
    LeQuang JA
    J Clin Aesthet Dermatol; 2022 Nov; 15(11 Suppl 1):S3-S15. PubMed ID: 36405422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
    Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
    Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
    [No Abstract]   [Full Text] [Related]  

  • 8. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
    Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
    Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
    [No Abstract]   [Full Text] [Related]  

  • 9. The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous Melanoma.
    Podlipnik S; Martin BJ; Morgan-Linnell SK; Bailey CN; Siegel JJ; Petkov VI; Puig S
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
    Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
    Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma.
    Dubin DP; Dinehart SM; Farberg AS
    Am J Clin Dermatol; 2019 Dec; 20(6):763-770. PubMed ID: 31359351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
    Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
    J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
    Scott AM; Dale PS; Conforti A; Gibbs JN
    Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
    Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D
    J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
    Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
    J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Utility of Dermoscopy and 31-Gene Expression Profiling by Dermatology Providers in Melanoma Management Care.
    Witkowski A; Lee C; Latour E; Vetto J; Ludzik J
    J Drugs Dermatol; 2022 Dec; 21(12):1347-1352. PubMed ID: 36468965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
    Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
    J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma.
    Nguyen BT; Kim RS; Bretana ME; Kegley E; Schefler AC
    Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):421-427. PubMed ID: 29185101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
    Amaral T; Sinnberg T; Chatziioannou E; Niessner H; Leiter U; Keim U; Forschner A; Dwarkasing J; Tjien-Fooh F; Wever R; Flatz L; Eggermont A; Forchhammer S
    Eur J Cancer; 2023 Mar; 182():155-162. PubMed ID: 36739215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions.
    Farberg AS; Glazer AM; White R; Rigel DS
    J Drugs Dermatol; 2017 May; 16(5):428-431. PubMed ID: 28628677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.